FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285043344> ?p ?o ?g. }

• W4285043344 endingPage "1593" @default.
• W4285043344 startingPage "1587" @default.
• W4285043344 abstract "Background Second-generation anaplastic lymphoma kinase (ALK) gene targeted tyrosine kinase inhibitors (TKIs) alectinib and brigatinib have shown efficacy as front-line treatments for ALK-positive non–small cell lung cancer (NSCLC). No head-to-head data are currently available for brigatinib vs alectinib in the ALK-TKI–naive population.Objective To estimate the relative overall survival (OS) for brigatinib vs alectinib with indirect treatment comparisons (ITCs) using ALEX and ALTA-1L clinical trial data.Methods The latest aggregate data from the ALEX trial and final patient-level data from ALTA-1L were used. ITCs were conducted with/without treatment crossover adjustments to estimate relative OS. Bucher methods, anchored matching-adjusted indirect comparisons (MAICs) and unanchored MAICs were employed in ITCs without treatment crossover adjustments. An inverse probability of censoring weight Cox model, a marginal structure model and rank-preserving structural failure time models (with/without re-censoring) within an anchored MAIC were used in ITCs with treatment crossover adjustments. Hazard ratios (HRs) and 95% confidence intervals (CIs) were reported.Results HRs for brigatinib vs alectinib for relative OS generated from ITCs without treatment crossover adjustments ranged from 0.90 (95% CI: 0.59–1.38) in the unanchored MAIC to 1.20 (95% CI: 0.69–2.11) using the Bucher method. Methods employing treatment switching adjustments estimated HRs for relative OS ranging from 0.74 (95% CI: 0.38–1.45) to 1.11 (95% CI: 0.63–1.94). Results from all ITCs did not indicate statistically different survival profiles.Conclusion Regardless of ITC methodology, OS is comparable for brigatinib vs alectinib in patients with ALK+ NSCLC previously untreated with an ALK inhibitor." @default.
• W4285043344 created "2022-07-13" @default.
• W4285043344 creator A5013551992 @default.
• W4285043344 creator A5023593985 @default.
• W4285043344 creator A5037746437 @default.
• W4285043344 creator A5047349474 @default.
• W4285043344 creator A5048231332 @default.
• W4285043344 creator A5051283101 @default.
• W4285043344 creator A5082517668 @default.
• W4285043344 creator A5083773336 @default.
• W4285043344 creator A5085150364 @default.
• W4285043344 creator A5086765625 @default.
• W4285043344 date "2022-07-29" @default.
• W4285043344 modified "2023-10-12" @default.
• W4285043344 title "Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase–positive non–small cell lung cancer using data from ALEX and final results from ALTA-1L" @default.
• W4285043344 cites W2005947177 @default.
• W4285043344 cites W2017979374 @default.
• W4285043344 cites W2031494655 @default.
• W4285043344 cites W2043976215 @default.
• W4285043344 cites W2071066672 @default.
• W4285043344 cites W2168106545 @default.
• W4285043344 cites W2172010139 @default.
• W4285043344 cites W2624310346 @default.
• W4285043344 cites W2802389870 @default.
• W4285043344 cites W2894476389 @default.
• W4285043344 cites W2991627091 @default.
• W4285043344 cites W3007156832 @default.
• W4285043344 cites W3022131485 @default.
• W4285043344 cites W3022263550 @default.
• W4285043344 cites W3030700619 @default.
• W4285043344 cites W3128646645 @default.
• W4285043344 cites W3168056273 @default.
• W4285043344 cites W3200994971 @default.
• W4285043344 cites W4281394950 @default.
• W4285043344 doi "https://doi.org/10.1080/03007995.2022.2100653" @default.
• W4285043344 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35815801" @default.
• W4285043344 hasPublicationYear "2022" @default.
• W4285043344 type Work @default.
• W4285043344 citedByCount "2" @default.
• W4285043344 countsByYear W42850433442022 @default.
• W4285043344 crossrefType "journal-article" @default.
• W4285043344 hasAuthorship W4285043344A5013551992 @default.
• W4285043344 hasAuthorship W4285043344A5023593985 @default.
• W4285043344 hasAuthorship W4285043344A5037746437 @default.
• W4285043344 hasAuthorship W4285043344A5047349474 @default.
• W4285043344 hasAuthorship W4285043344A5048231332 @default.
• W4285043344 hasAuthorship W4285043344A5051283101 @default.
• W4285043344 hasAuthorship W4285043344A5082517668 @default.
• W4285043344 hasAuthorship W4285043344A5083773336 @default.
• W4285043344 hasAuthorship W4285043344A5085150364 @default.
• W4285043344 hasAuthorship W4285043344A5086765625 @default.
• W4285043344 hasBestOaLocation W42850433441 @default.
• W4285043344 hasConcept C117643217 @default.
• W4285043344 hasConcept C126322002 @default.
• W4285043344 hasConcept C137668524 @default.
• W4285043344 hasConcept C142724271 @default.
• W4285043344 hasConcept C143998085 @default.
• W4285043344 hasConcept C207103383 @default.
• W4285043344 hasConcept C2776232967 @default.
• W4285043344 hasConcept C2776256026 @default.
• W4285043344 hasConcept C2779220645 @default.
• W4285043344 hasConcept C2779422266 @default.
• W4285043344 hasConcept C2779750558 @default.
• W4285043344 hasConcept C2908647359 @default.
• W4285043344 hasConcept C44249647 @default.
• W4285043344 hasConcept C71924100 @default.
• W4285043344 hasConcept C99454951 @default.
• W4285043344 hasConceptScore W4285043344C117643217 @default.
• W4285043344 hasConceptScore W4285043344C126322002 @default.
• W4285043344 hasConceptScore W4285043344C137668524 @default.
• W4285043344 hasConceptScore W4285043344C142724271 @default.
• W4285043344 hasConceptScore W4285043344C143998085 @default.
• W4285043344 hasConceptScore W4285043344C207103383 @default.
• W4285043344 hasConceptScore W4285043344C2776232967 @default.
• W4285043344 hasConceptScore W4285043344C2776256026 @default.
• W4285043344 hasConceptScore W4285043344C2779220645 @default.
• W4285043344 hasConceptScore W4285043344C2779422266 @default.
• W4285043344 hasConceptScore W4285043344C2779750558 @default.
• W4285043344 hasConceptScore W4285043344C2908647359 @default.
• W4285043344 hasConceptScore W4285043344C44249647 @default.
• W4285043344 hasConceptScore W4285043344C71924100 @default.
• W4285043344 hasConceptScore W4285043344C99454951 @default.
• W4285043344 hasIssue "9" @default.
• W4285043344 hasLocation W42850433441 @default.
• W4285043344 hasLocation W42850433442 @default.
• W4285043344 hasOpenAccess W4285043344 @default.
• W4285043344 hasPrimaryLocation W42850433441 @default.
• W4285043344 hasRelatedWork W2148613928 @default.
• W4285043344 hasRelatedWork W2503069423 @default.
• W4285043344 hasRelatedWork W2532503897 @default.
• W4285043344 hasRelatedWork W2624310346 @default.
• W4285043344 hasRelatedWork W2764093873 @default.
• W4285043344 hasRelatedWork W2799723181 @default.
• W4285043344 hasRelatedWork W2887042787 @default.
• W4285043344 hasRelatedWork W2987457019 @default.
• W4285043344 hasRelatedWork W4226257711 @default.
• W4285043344 hasRelatedWork W4312814407 @default.
• W4285043344 hasVolume "38" @default.

• next